Copyright 2009 by the Society for Neuro-Oncology
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas
Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China (Y.L., T.J., K.Z., L.X., B.C., G.L., X.Q.); Department of Neurosurgery, First Affiliated Hospital, China Medical University, Shenyang, China (Y.L.); LIAMA Center for Computational Medicine, National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China (T.J., S.W.S.); Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA (W.Z.)
Address correspondence to Sonya W. Song, LIAMA Center for Computational Medicine, National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China (weisonyasong{at}gmail.com) or Tao Jiang, Tiantan Hospital, Beijing, China (jiangtao369{at}sohu.com).
 |
Abstract |
|---|
Insulin-like growth factor binding protein 2 (IGFBP-2) is a malignancy-associated protein measurable in tumors and blood. Increased IGFBP-2 is associated with shortened survival of advanced glioma patients. Thus, we examined plasma IGFBP-2 levels in glioma patients and healthy controls to evaluate its value as a plasma biomarker for glioma. Plasma IGFBP-2 levels in 196 patients with newly diagnosed glioma and 55 healthy controls were analyzed using an IGFBP-2 ELISA kit. Blood was collected before surgery, after two-cycle adjuvant chemotherapy, and at recurrence. Plasma IGFBP-2 levels were correlated with disease-free survival (DFS) using Cox regression analyses. We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients (n = 43 for grade III glioma; n = 72 for glioblastoma multiforme [GBM]) than in healthy controls (n = 55; p < 0.001) and low-grade (grade II) glioma patients (n = 81; p < 0.001). No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls. After recurrence, plasma IGFBP-2 levels were significantly increased in GBM patients (n = 26; p < 0.001). Preoperative plasma IGFBP-2 levels were significantly correlated with DFS in GBM patients (hazard ratio, 1.404; 95% confidence interval, 1.078–1.828; p = 0.012). We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and DFS in patients with GBM. Longitudinal studies with a larger study population are needed to confirm these findings.
Keywords: glioma, IGFBP-2, plasma surrogate biomarker, prognosis, recurrence
Received July 28, 2008; Accepted December 10, 2008
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. M. Probst-Hensch, J. H.B. Steiner, P. Schraml, Z. Varga, U. Zurrer-Hardi, M. Storz, D. Korol, M. K. Fehr, D. Fink, B. C. Pestalozzi, et al. IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity Clin. Cancer Res., February 1, 2010; 16(3): 1025 - 1032. [Abstract] [Full Text] [PDF]
|
|